JAK2 and head and neck squamous cell carcinoma: CTSG inhibits HNSCC proliferation and metastasis in vivo and in vitro, which has the potential to be an oncogenic factor for HNSCC by focusing on the JAK2/STAT3 signaling pathway 47.